Back
Results - Announcements
Alkem Laboratories Ltd consolidated sales up 3.80% on year in Q2FY2026, net profit saw a strong growth of 107.20%
14-Aug-2026, 05:35
Alkem Laboratories Ltd share price declined by 0.94% to Rs 5418.75. The Company's net profit jumped 107.20% to Rs 521.49 crore, while revenue from operations slightly gained 3.80% to Rs 3740.15 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.69%. It has marginally improved by 0.66% over last one week and climbed by 11.20% in last one month while the market capitalization of Alkem Laboratories Ltd has softened by 3.76% and 1.21% in the same period respectively. Profit before tax (PBT) of Alkem Laboratories Ltd stood at Rs 771.99 crore in Q2 FY26, easing 0.13% year-on-year, and surging by 82.57% quarter-on-quarter. EBITDA came in at Rs 613 crore, gaining 1.78% YoY and rallying 93.27% sequentially. Total expenses marginally dropped 3.68% to Rs 3074.29 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 910.02 crore, posting a minor increase of 1.69% YoY, while employee benefits expense was at Rs 808.9 crore, surging 13.59% YoY. For the TTM ended FY26, revenue from operations rose 13.48% to Rs 14712.27 crore, while net profit grew slightly 6.19% to Rs 2353.13 crore, compared to previous TTM. EBITDA jumped by 204231% to Rs 2421.86 crore, and PBT improved 13.61% to Rs 2870.89 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1963.03 crore in FY26, as against Rs 1912.84 crore in FY25. Alkem Laboratories Ltd gained 0.52% in last one year, outperforming the benchmark BSE Sensex which has slipped by 3.05% during the same period.
Alkem Laboratories Ltd share price declined by 0.94% to Rs 5418.75. The Company's net profit jumped 107.20% to Rs 521.49 crore, while revenue from operations slightly gained 3.80% to Rs 3740.15 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, rising 4.69%. It has marginally improved by 0.66% over last one week and climbed by 11.20% in last one month while the market capitalization of Alkem Laboratories Ltd has softened by 3.76% and 1.21% in the same period respectively. Profit before tax (PBT) of Alkem Laboratories Ltd stood at Rs 771.99 crore in Q2 FY26, easing 0.13% year-on-year, and surging by 82.57% quarter-on-quarter. EBITDA came in at Rs 613 crore, gaining 1.78% YoY and rallying 93.27% sequentially. Total expenses marginally dropped 3.68% to Rs 3074.29 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 910.02 crore, posting a minor increase of 1.69% YoY, while employee benefits expense was at Rs 808.9 crore, surging 13.59% YoY. For the TTM ended FY26, revenue from operations rose 13.48% to Rs 14712.27 crore, while net profit grew slightly 6.19% to Rs 2353.13 crore, compared to previous TTM. EBITDA jumped by 204231% to Rs 2421.86 crore, and PBT improved 13.61% to Rs 2870.89 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1963.03 crore in FY26, as against Rs 1912.84 crore in FY25. Alkem Laboratories Ltd gained 0.52% in last one year, outperforming the benchmark BSE Sensex which has slipped by 3.05% during the same period.